Enliven Therapeutics (ELVN) Free Cash Flow (2019 - 2026)
Enliven Therapeutics (ELVN) reported Free Cash Flow of -$19.3 million for Q1 2026, up 20.11% on a YoY basis from -$16.1 million in Q1 2025, and down 21.8% sequentially from -$15.8 million in Q4 2025.
Enliven Therapeutics (ELVN) Free Cash Flow (2019 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 8 years of Free Cash Flow data on file, last reported at -$19.3 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 20.11% year-over-year to -$19.3 million; the trailing twelve-month figure through Mar 2026 stood at -$65.6 million (up 11.35% YoY), and the FY2025 full-year result was -$70.5 million, up 3.79% from the prior year.
- Free Cash Flow slipped to -$19.3 million in Q1 2026, from -$15.8 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$6.5 million in Q3 2022 to a low of -$24.1 million in Q1 2025.
- A 5-year average of -$15.1 million and a median of -$15.8 million in 2025 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow soared 40.73% in 2022 and tumbled 146.25% in 2023, its largest moves.
- Tracing ELVN's Free Cash Flow over 5 years: stood at -$8.2 million in 2022, then slumped by 51.54% to -$12.5 million in 2023, then sank by 37.67% to -$17.2 million in 2024, then grew by 7.93% to -$15.8 million in 2025, then retreated by 21.8% to -$19.3 million in 2026.
- Business Quant data shows ELVN's Free Cash Flow at -$19.3 million in Q1 2026, -$15.8 million in Q4 2025, and -$13.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | -19.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.29 Mn |
| Mar 31, 2026 | -19.29 Mn |
| Dec 31, 2025 | -15.84 Mn |
| Dec 31, 2025 | -15.84 Mn |
| Sep 30, 2025 | -13.28 Mn |
| Sep 30, 2025 | -13.28 Mn |
| Jun 30, 2025 | -17.20 Mn |
| Jun 30, 2025 | -17.20 Mn |
| Mar 31, 2025 | -24.15 Mn |
| Mar 31, 2025 | -24.15 Mn |
| Dec 31, 2024 | -17.20 Mn |
| Dec 31, 2024 | -17.20 Mn |
| Sep 30, 2024 | -12.21 Mn |
| Sep 30, 2024 | -12.21 Mn |
| Jun 30, 2024 | -20.44 Mn |
| Jun 30, 2024 | -20.44 Mn |
| Mar 31, 2024 | -23.38 Mn |
| Mar 31, 2024 | -23.38 Mn |
| Dec 31, 2023 | -12.50 Mn |
| Dec 31, 2023 | -12.50 Mn |